Synlab AG (XETRA: SYAB.DE) AI-Powered Stock Analysis
See how Synlab AG scores across key metrics like financial growth, valuation, and market position on the XETRA, using AI-driven evaluation.
SYAB.DE●XETRA
HealthcareMedical - Diagnostics & Research
€11.06
€0.02(0.18%)
German Market opens in 43h 28m
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerSynlab AG (XETRA: SYAB.DE) Stock Overall Grade
Synlab AG's grade for its XETRA listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Synlab AG's overall XETRA stock rating.
Forecast
B+Score
75/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
AScore
80/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
C+Score
50/100Synlab AG (XETRA: SYAB.DE) AI-Powered Stock Analysis
On the XETRA, SYAB.DE demonstrates Good performance with an overall Forecast Score of 75/100 (B+), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (80/100, A) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), the XETRA-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(XETRA: SYAB.DE) Component Analysis Explained
Understand the key factors behind each Synlab AG (XETRA: SYAB.DE) stock grade, including financials, comparisons, and forecasts.